Laryngeal Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LRY018 MIFTS: 44	Laryngeal Squamous Cell Carcinoma Categories: Cancer diseases, Oral diseases, Respiratory diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Laryngeal Squamous Cell Carcinoma

MalaCards integrated aliases for Laryngeal Squamous Cell Carcinoma:

Name: Laryngeal Squamous Cell Carcinoma ¹² ⁵⁴ ¹⁵ ¹⁷

Epidermoid Carcinoma of the Larynx ¹²

Squamous Cell Carcinoma of Larynx ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases Skin diseases Oral diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:2876

NCIt ⁴⁹ C4044

SNOMED-CT ⁶⁷ 707358000

EFO ¹⁷ EFO_0006352

UMLS ⁷¹ C0280324

Sources

Summaries for Laryngeal Squamous Cell Carcinoma

Disease Ontology : ¹² A laryngeal carcinoma that has material basis in squamous cells.

MalaCards based summary : Laryngeal Squamous Cell Carcinoma, also known as epidermoid carcinoma of the larynx, is related to larynx cancer and squamous cell papilloma. An important gene associated with Laryngeal Squamous Cell Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Docetaxel and Pembrolizumab have been mentioned in the context of this disorder. Affiliated tissues include lymph node, thyroid and endothelial, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Laryngeal Squamous Cell Carcinoma

Diseases related to Laryngeal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 309)

#	Related Disease	Score	Top Affiliating Genes
1	larynx cancer	33.3	TP53 TERT NME1 MIR21 EGFR CDKN2A
2	squamous cell papilloma	31.8	TP53 CDKN2A
3	papilloma	31.7	TP53 EGFR CDKN2A CDH1 CCND1
4	in situ carcinoma	31.1	TP53 EGFR CDKN2A CDH1 CCND1
5	oropharynx cancer	31.0	TP53 EGFR CDKN2A CDH1 CCND1
6	gastroesophageal reflux	30.9	TP53 TERT EGFR CCND1
7	basaloid squamous cell carcinoma	30.8	TP53 EGFR CDKN2A
8	verrucous carcinoma	30.8	TP53 EGFR CDKN2A CCND1
9	b-cell lymphoma	30.8	TP53 MIR21 MALAT1 HOTAIR CDKN2A CCND1
10	squamous cell carcinoma	30.8	TP53 NME1 NEAT1 MALAT1 HOTAIR H19
11	laryngeal disease	30.8	TP53 MIR21 CDKN2A CCND1
12	suppressor of tumorigenicity 3	30.7	TP53 CDKN2A
13	suppression of tumorigenicity 12	30.7	TP53 TERT EGFR CDKN2A CDH1 CCND1
14	thymoma	30.7	TP53 EGFR CDKN2A CCND1
15	keratosis	30.6	TP53 EGFR CDKN2A
16	adenoid cystic carcinoma	30.6	TP53 EGFR CDKN2A CDH1 CCND1
17	intrahepatic cholangiocarcinoma	30.5	TP53 EGFR CDH1 CCND1 CCAT1
18	squamous cell carcinoma, head and neck	30.5	TP53 NME1 MIR21 HOTAIR H19 EGFR
19	retinitis pigmentosa 11	30.4	TP53 NEAT1 HOTAIR EGFR CDKN2A
20	hypopharynx cancer	30.4	TP53 NME1 LINC01537 EGFR CDKN2A CDH1
21	retinoblastoma	30.4	TP53 MALAT1 HOTAIR CDKN2A CCND1 CCAT1
22	thyroid cancer, nonmedullary, 1	30.4	NEAT1 MALAT1 HOTAIR H19
23	leukemia, chronic myeloid	30.2	TP53 NME1 HOTAIR H19 EGFR CCND1
24	adenocarcinoma	30.1	TP53 MALAT1 H19 EGFR CDKN2A CDH1
25	lung cancer susceptibility 3	29.6	TP53 TERT MIR21 MALAT1 HOTAIR H19
26	renal cell carcinoma, nonpapillary	29.5	TP53 NME1 MIR21 MALAT1 HOTAIR H19
27	cholangiocarcinoma	29.4	TP53 TERT NEAT1 MIR21 MALAT1 H19
28	osteogenic sarcoma	28.3	TP53 NEAT1 MALAT1 HOXA11-AS HOTAIR H19
29	nasopharyngeal carcinoma	28.2	TP53 TERT NME1 NEAT1 MIR21 MALAT1
30	pancreatic cancer	28.0	TP53 TERT NEAT1 MIR21 MALAT1 HOTAIR
31	glioma	27.9	TP53 NEAT1 MIR21 MALAT1 HOXA11-AS HOTAIR
32	colorectal cancer	27.4	TP53 TERT NME1 NEAT1 MIR21 MALAT1
33	esophageal leukoplakia	10.7	TP53 CCND1
34	prostate squamous cell carcinoma	10.7	TP53 CDKN2A
35	pancreatic foamy gland adenocarcinoma	10.7	TP53 CCND1
36	endometrial squamous cell carcinoma	10.7	TP53 CDKN2A
37	vulvar intraepithelial neoplasia	10.6	TP53 CDKN2A CDH1
38	malignant peritoneal mesothelioma	10.6	EGFR CDKN2A
39	nodular malignant melanoma	10.6	TP53 CDKN2A CCND1
40	ovarian seromucinous carcinoma	10.6	TP53 CDKN2A
41	spitz nevus	10.6	TP53 CDKN2A
42	bowenoid papulosis	10.6	TERT CDKN2A CCND1
43	esophageal basaloid squamous cell carcinoma	10.6	TP53 EGFR
44	skin papilloma	10.6	TP53 EGFR CCND1
45	vulvar disease	10.6	TP53 EGFR CDKN2A
46	adult malignant schwannoma	10.6	TP53 CDKN2A AURKA
47	rhabdoid cancer	10.6	TP53 CDKN2A CCND1
48	sarcomatoid transitional cell carcinoma	10.6	TP53 CDH1
49	peritoneum cancer	10.6	TP53 EGFR CDKN2A
50	anus cancer	10.6	TP53 EGFR CDKN2A

Graphical network of the top 20 diseases related to Laryngeal Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Laryngeal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	9.66	AURKA EGFR
2	Decreased viability	GR00055-A-2	9.66	AURKA EGFR
3	Decreased viability	GR00221-A-1	9.66	AURKA CDH1 CDKN2A EGFR NME1
4	Decreased viability	GR00221-A-2	9.66	AURKA NME1
5	Decreased viability	GR00221-A-3	9.66	CDKN2A
6	Decreased viability	GR00221-A-4	9.66	AURKA CDKN2A EGFR
7	Decreased viability	GR00231-A	9.66	AURKA
8	Decreased viability	GR00249-S	9.66	AURKA NME1
9	Decreased viability	GR00301-A	9.66	CDH1
10	Decreased viability	GR00402-S-2	9.66	AURKA CDH1 NME1

MGI Mouse Phenotypes related to Laryngeal Squamous Cell Carcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.23	AURKA CCND1 CDH1 CDKN2A EGFR NME1

Sources

Drugs & Therapeutics for Laryngeal Squamous Cell Carcinoma

Drugs for Laryngeal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Synonyms:

(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate

01885_FLUKA

114977-28-5

4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate

AC1L3WHJ

AC-383

ANX-514

BIND-014

C11231

CHEBI:4672

CHEMBL92

CID148124

D07866

DB01248

docetaxel

Docetaxel

Docetaxel (INN)

docetaxel 114977-28-5

Docetaxel anhydrous

Docetaxel hydrate

Docetaxel trihydrate

Docetaxel, trihydrate

Docetaxel, Trihydrate

Docetaxol

EmDOC

HMS2089K08

InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5

MolPort-003-847-005

nchembio.188-comp8

nchembio.2007.34-comp7

nchembio.573-comp11

nchembio853-comp8

N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel

N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel

N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol

N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol

N-debenzoyl-N-Boc-10-deacetyl taxol

N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol

NSC-628503

PSMA-targeted docetaxel nanoparticle

RP-56976

SDP-014

Taxoltere metro

Taxotere

Taxotere (TN)

Taxotere(R)

TXL

XRP-6976L

Pembrolizumab

Approved

Phase 1, Phase 2

1374853-91-4

Cetuximab

Approved

Phase 2

205923-56-4

56842117 2333

Synonyms:

205923-56-4

Anti EGFR

cetuximab

Cetuximab

Cétuximab

Cetuximab (genetical recombination)

Cetuximab (genetical recombination) (JAN)

Cetuximab (USAN/INN)

Cetuximabum

D03455

Erbitux

Erbitux (TN)

IMC-C225

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Synonyms:

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

157069-30-2

33069-62-4

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

7 Epi taxol

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.

7-epi-Paclitaxel

7-Epipaclitaxel

7-Epi-paclitaxel

7-epi-Taxol

7-Epitaxol

7-Epi-taxol

AB00513812

ABI 007

abi-007

ABI007

ABI-007

Abraxane

Abraxane (TN)

Abraxane I.V. Suspension

Abraxis BioScience brand of albumin-bound paclitaxel

AC1L1IOG

AC1L1VJI

AC1L9AVF

AC-675

ACon1_002231

albumin-bound paclitaxel

Ambotz33069-62-4

ANX-513

Anzatax

Asotax

BIDD:PXR0046

Bio-0076

Bio1_000362

Bio1_000851

Bio1_001340

Bio2_000416

Bio2_000896

BMS 181339-01

BMS-181339

BMS-181339-01

BPBio1_000320

BRD-A23723433-001-01-2

BRD-A28746609-001-04-0

BRD-K62008436-001-03-1

Bris taxol

Bristaxol

BSPBio_000290

BSPBio_001152

BSPBio_002614

C07394

C466458

C47H51NO14

Capxol

CCRIS 8143

CHEBI:103439

CHEBI:45863

CHEMBL100910

CHEMBL418410

CHEMBL48

CID36314

CID441276

CID4666

CID6713921

CID6915727

cMAP_000068

CPD-8718

D00491

DB01229

DHP-107

DHP-208

DivK1c_000441

DRG-0190

DTS-301

Ebetaxel

EmPAC

Epitaxol

EU-0101201

Genaxol

Genetaxyl

Genexol

Genexol-PM

HMS1362J13

HMS1568O12

HMS1792J13

HMS1922K08

HMS1990J13

HMS2090D07

HMS2093K15

HMS501G03

HSDB 6839

I06-0014

IDI1_000441

IDI1_002171

Intaxel

KBio1_000441

KBio2_000492

KBio2_002016

KBio2_002509

KBio2_003060

KBio2_004584

KBio2_005077

KBio2_005628

KBio2_007152

KBio2_007645

KBio3_000903

KBio3_000904

KBio3_001834

KBio3_002987

KBioGR_000492

KBioGR_001893

KBioGR_002509

KBioSS_000492

KBioSS_002016

KBioSS_002517

LipoPac

LMPR0104390001

Lopac0_001201

LS-31070

MBT 0206

MEGxp0_001940

Micellar Paclitaxel

Mitotax

MLS000863266

MLS001077297

MLS002154218

MLS002172439

MLS002695976

MolPort-001-742-627

MolPort-003-665-783

MolPort-003-932-365

MPI-5018

nab-paclitaxel

Nanotaxel

NCGC00024995-02

NCGC00024995-03

NCGC00024995-04

NCGC00024995-05

NCGC00024995-06

NCGC00024995-07

NCGC00164367-01

NCGC00164367-02

NCGC00164367-03

nchembio.188-comp1

nchembio.2007.34-comp9

nchembio.215-comp9

nchembio853-comp6

NCI60_000601

Neuro_000060

NINDS_000441

NK 105

Nova-12005

NP-010981

NSC 125973

NSC125973

NSC-125973

NSC358882

OAS-PAC-100

OncoGel

Onxal

Onxol

Onxol, Taxol, Nov-Onxol, Paclitaxel

P1632

Paclical

Pacligel

paclitaxel

Paclitaxel

Paclitaxel (JAN/USP)

Paclitaxel (JAN/USP/INN)

Paclitaxel (Taxol)

Paclitaxel [USAN:INN:BAN]

Paclitaxel, (4 alpha)-isomer

Paxceed

Paxene

Paxoral

Plaxicel

Praxel

Prestwick0_000155

Prestwick1_000155

Prestwick2_000155

Prestwick3_000155

Probes2_000350

QW 8184

S1150_Selleck

S-8184 Paclitaxel Injectable Emulsion

SDCCGMLS-0066823.P001

SDP-013

SMP1_000228

SMR000394086

SMR000857385

SPBio_000943

SPBio_002229

Spectrum_001536

SPECTRUM1503908

Spectrum2_000872

Spectrum3_001057

Spectrum4_001197

Spectrum5_001491

ST50306996

T 7402

T1912_SIGMA

T7191_SIGMA

T7402_SIGMA

TA1

TaxAlbin

Taxol

TAXOL

TAXOL (TN)

Taxol a

Taxol A

Taxol Konzentrat

TAXOL, 10-EPI,

Taxol, bris

Taxol.RTM. (Registered Trademark)

TXL

UNII-P88XT4IS4D

UPCMLD-DP108:001

UPCMLD-DP108:002

Vascular Wrap

weekly paclitaxel

Xorane

Yewtaxan

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904 498142

Synonyms:

(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum

/h1-3H2,(H,7,8)(H,9,10)

1,1-Cyclobutanedicarboxylate diammine platinum (II)

1,1-Cyclobutanedicarboxylate diammine platinum(II)

2*-1

2*1H2

41575-94-4

70903-55-8

AC-1457

AC1L8I6U

Ambap41575-94-4

azanide

Blastocarb

BSPBio_003145

C 2538

C2043

C2538_SIGMA

C6H10N2O4Pt

Carbopaltin

Carboplat

carboplatin

Carboplatin

Carboplatin (JAN/USP/INN)

Carboplatin (USAN)

Carboplatin [USAN:INN:BAN:JAN]

Carboplatine

Carboplatine [French]

Carboplatino

Carboplatino [Spanish]

Carboplatinum

Carboplatinum [Latin]

Carbosin

Carbotec

Cbdca

CBDCA

CCRIS 3404

CHEBI:31355

CHEMBL1351

CHEMBL288376

CID10339178

CID2567

CID38904

CID426756

CID498142

CID5352133

CID6398587

CID6603770

cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum

cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)

cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

cis-diammine(1,1-cyclobutanedicarboxylato)platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum

cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(cyclobutanedicarboxylato)platinum II

Cyclobutane-1,1-dicarboxylate

cyclobutane-1,1-dicarboxylic acid

D01363

DB00958

Diammine(1,1-cyclobutanedicarboxylato)platinum (II)

Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum

diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum

Diammine-1,1-cyclobutane dicarboxylate platinum II

DivK1c_000892

EINECS 255-446-0

Ercar

EU-0100230

HMS1921J16

HMS2090M05

HMS2092B22

HMS502M14

HSDB 6957

I14-2390

IDI1_000892

InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6

IUPAC: Azane

JM 8

JM8

JM-8

KBio1_000892

KBio2_002009

KBio2_004577

KBio2_007145

KBio3_002645

KBioGR_000713

KBioSS_002009

Lopac0_000230

Lopac-C-2538

LS-117689

MolPort-003-665-501

MolPort-003-845-609

NCGC00015223-01

NCGC00093695-01

NCGC00094961-01

NCGC00094961-02

NCGC00094961-03

NCGC00162099-01

NCGC00162099-02

NCGC00167800-01

NCGC00178242-01

nchembio.573-comp10

nchembio773-comp2

nchembio873-comp3

Nealorin

Neocarbo

NINDS_000892

NSC 201345

NSC 241240

NSC201345

NSC241240

NSC-241240

Paraplatin

Paraplatin (TN)

Paraplatin, Carboplatin

Paraplatin-AQ

Platinum(+2) Cation

platinum(2+)

Platinum(II), (1, 1-cyclobutanedicar

Platinum, {diammine[1,1-cyclobut

Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)

Ribocarbo

S1215_Selleck

SPBio_000716

Spectrum_001529

SPECTRUM1502106

Spectrum2_000898

Spectrum3_001503

Spectrum4_000337

Spectrum5_001094

UNII-BG3F62OND5

Trioxsalen

Approved

Phase 2

3902-71-4

5585

Synonyms:

2',4,8-Trimethylpsoralen

2,5,9-Trimethyl-7H-furo(3,2-g)benzopyran-7-one

4,5',8-Trimethylpsoralen

4,8,5'-Trimethylpsoralen

6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylate, delta-lactone

6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylate, δ-lactone

6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone

6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylic acid, δ-lactone

6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylate, delta-lactone

6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone

6-Hydroxy-β,2,7-trimethyl-5-benzofuranacrylate, δ-lactone

6-hydroxy-β,2,7-trimethyl-5-benzofuranacrylic acid, δ-lactone

6-Hydroxy-β,2,7-trimethyl-5-benzofuranacrylic acid, δ-lactone

ICN brand OF trioxsalen

Trimethylpsoralen

Trioxisaleno

Trioxisalenum

Trioxsalen

Trioxysalen

Trioxysalene

Trioxysalenum

Trisoralen

leucovorin

Approved

Phase 2

58-05-9

6006 143

Synonyms:

(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate

(6R,S)-5-Formyltetrahydrofolate

10-Formyl-7,8-dihydrofolate

10-Formyl-7,8-dihydrofolic acid

5 Formyltetrahydrofolate

5 Formyltetrahydropteroylglutamate

5-Formyl-5,6,7,8-tetrahydrofolate

5-Formyl-5,6,7,8-tetrahydrofolic acid

5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid

5-formyltetrahydrofolate

5-Formyltetrahydrofolate

5-formyltetrahydrofolic acid

5-Formyltetrahydrofolic acid

5-Formyltetrahydropteroylglutamate

5-Formyltetrahydropteroylglutamic acid

5-formylTHF

Acid, folinic

Acide folinique

Acido folinico

Calcium citrovorum factor

Calcium folinate

Calcium leucovorin

Citrovorum factor

Factor, citrovorum

Folinate

Folinate, calcium

Folinic acid

Folinic acid calcium salt

Folinic acid calcium salt USP27

Folinic acid SF

Folinic acid-SF

L(-)-5-Formyl-5,6,7,8-tetrahydrofolate

L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid

Leucal

Leucovorin

Leucovorin calcium

Leucovorin folinic acid

Leucovorin, (D)-isomer

Leucovorin, (DL)-isomer

Leucovorin, (R)-isomer

Leucovorin, calcium

Leucovorin, calcium (1:1) salt

Leucovorin, calcium (1:1) salt, (DL)-isomer

Leucovorin, calcium (1:1) salt, pentahydrate

Leucovorin, monosodium salt

Leucovorinum

Leukovorin

Leukovorum

Levoleucovorin

L-leucovorin

L-Leucovorin

L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid

Monosodium salt leucovorin

N(5)-Formyltetrahydrofolate

N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid

N5-Formyl-5,6,7,8-tetrahydrofolate

N5-Formyl-5,6,7,8-tetrahydrofolic acid

N5-Formyltetrahydrofolate

N5-Formyltetrahydrofolic acid

Rescuvolin

Welcovorin

Wellcovorin

Tegafur

Approved, Investigational

Phase 2

17902-23-7

5386

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Synonyms:

(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid

01769_FLUKA

2d0k

33609-88-0

36653-55-1 (mono-potassium salt)

59-30-3

6484-89-5 (mono-hydrochloride salt)

AC-11682

AC1L1LNX

Acfol (Spain)

Acide folique

Acide folique [INN-French]

Acido folico

ácido fólico

Acido folico [INN-Spanish]

Acidum folicum

Acidum folicum [INN-Latin]

Acifolic

AI3-26387

AKOS000503224

Antianemia factor

Apo-Folic

ARONIS014410

b9, Vitamin

BIDD:ER0563

BIDD:GT0641

BIF0608

bmse000299

BPBio1_000654

BSPBio_000594

BSPBio_002338

C00504

C20H20N6O6

CAS-59-30-3

CCRIS 666

CHEBI:27470

CHEMBL1622

CID6037

CPD000471860

Cytofol

D00070

DB00158

DivK1c_000494

Dosfolat b activ

Dosfolat B activ

EINECS 200-419-0

F0043

F7876_SIAL

F7876_SIGMA

F8758_SIGMA

F8798_SIAL

F8890_SIGMA

Facid

Factor U

FOL

Folacid

Folacin

Folaemin

Folaemin [Netherlands]

Folan

Folasic (Australia)

Folate

Folbal

Folcidin

Folcidin (VAN)

Folcysteine

Foldine

Foldine [France]

Folettes

Foliamin

Folic

folic acid

Folic acid

Folic acid (JP15/USP/INN)

Folic acid (TN)

Folic acid [BAN:INN:JAN]

Folic acid [INN:BAN:JAN]

Folic acid dihydrate

Folic acid, (D)-isomer

Folic acid, (DL)-isomer

Folic acid, calcium salt (1:1)

Folic acid, monopotassium salt

Folic acid, monosodium salt

Folic acid, potassium salt

Folic acid, sodium salt

Folicet

Folicet (TN)

Folico

Folico (Italy)

Folina

Folina (Italy)

Folipac

Folsaeure

Folsan

Folsaure

Folsäure

Folsav

Folvite

Folvron

Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L

HMS1921D20

HMS2092N17

HMS501I16

HSDB 2002

IDI1_000494

Incafolic

InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s

KBio1_000494

KBio2_001861

KBio2_004429

KBio2_006997

KBio3_001558

KBioGR_002222

KBioSS_001861

Kyselina listova

Kyselina listova [Czech]

Liver lactobacillus casei factor

Liver Lactobacillus casei factor

LS-2157

Millafol

Mission prenatal

Mittafol

MLS001304016

MLS001335861

MolPort-004-285-551

N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid

N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid

N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid

N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid

N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid

N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate

N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid

N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid

NCGC00016265-01

NCGC00142391-01

nchembio.108-comp10

Nifolin

Nifolin [Denmark]

NINDS_000494

Novofolacid

Novofolacid [Canada]

N-Pteroyl-L-glutamate

N-pteroyl-L-glutamic acid

N-Pteroyl-L-glutamic acid

NSC 3073

PGA

PGA (VAN)

Prestwick_230

Prestwick3_000627

PteGlu

Pteroylglutamate

Pteroylglutamic acid

Pteroyl-L-glutamate

Pteroyl-L-glutamic acid

Pteroyl-L-monoglutamate

Pteroyl-L-monoglutamic acid

Pteroylmonoglutamate

Pteroylmonoglutamic acid

SAM002264616

SDCCGMLS-0066738.P001

Serum Folate Level

SMP2_000137

SMR000471860

SPBio_001357

Spectrum_001381

SPECTRUM1502020

Spectrum2_001459

Spectrum3_000749

Spectrum4_001751

Spectrum5_000602

UNII-935E97BOY8

Usaf cb-13

Vitamin B11

Vitamin b9

Vitamin B9

Vitamin Bc

Vitamin BC

Vitamin be

Vitamin Be

Vitamin m

Vitamin M

Arginyl-glycyl-aspartic acid

Phase 2

Immunoglobulins

Phase 1, Phase 2

Antibodies

Phase 1, Phase 2

Antineoplastic Agents, Immunological

Phase 1, Phase 2

Albumin-Bound Paclitaxel

Phase 2

Tubulin Modulators

Phase 2

Antimitotic Agents

Phase 2

Photosensitizing Agents

Phase 2

Dihematoporphyrin Ether

Phase 2

Dermatologic Agents

Phase 2

Hematoporphyrin Derivative

Phase 2

Ether

Phase 2

Micronutrients

Phase 2

Trace Elements

Phase 2

Vitamins

Phase 2

Antidotes

Phase 2

Vitamin B Complex

Phase 2

Folate

Phase 2

Protective Agents

Phase 2

Nutrients

Phase 2

Astragalus

Phase 2

Vitamin B9

Phase 2

Cola

Interventional clinical trials:

(show all 15)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging	Completed	NCT00565721	Phase 2	Fluciclatide Injection - (AH111585 (F18))
2	Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP)	Recruiting	NCT04030455	Phase 2	Carboplatin;Cisplatin;Docetaxel
3	A Phase I/II Study of Chemo Radiation Plus the Anti-Programmed Death-1 (Anti-PD-1) Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma	Active, not recruiting	NCT02759575	Phase 1, Phase 2	Pembrolizumab;Cisplatin
4	A Prospective Phase II Study of Involved Field Elective Volume De-Intensification for Oropharyngeal and Laryngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiation Therapy	Active, not recruiting	NCT03067610	Phase 2	chemotherapy
5	A Phase II Randomized Sham-Controlled Trial With Allocation Concealment and Blinded Patients and Assessors, Investigating Hyperbaric Oxygen as a Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx and Larynx	Not yet recruiting	NCT03843671	Phase 2	Hyperbaric oxygen
6	Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II	Terminated	NCT02068157	Phase 2	Photodynamic Therapy;Porfimer Sodium
7	A Phase II Double-blind and Randomized Trial Comparing Concurrent Chemoradiotherapy Plus PG2 Injection Versus Concurrent Chemoradiotherapy Plus Placebo in Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma	Terminated	NCT01720563	Phase 2	Astragalus polysaccharides 500 mg;Placebo
8	Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck	Withdrawn	NCT00006106	Phase 1	cisplatin;fluorouracil;ONYX-015
9	Quality of Life After Laser Cordectomy in Early Glottic Cancer	Unknown status	NCT02184403
10	Validation of a Screening Tool in Geriatric Oncology	Completed	NCT00963911
11	Hyperfractionation and Accelerated Fractionation in Comparison With Conventional Fractionation in Definitive Radiotherapy of Squamous Cell Carcinoma of Larynx, Oropharynx and Hypopharynx	Completed	NCT00291434
12	Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions	Completed	NCT02217358
13	Development and Validation of Nomograms to Precisely Predict Conditional Risk of Recurrence for Patients With Laryngeal Cancer: a Single-institutional Study	Recruiting	NCT03595410
14	Development and Validation of Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer: a Single-institutional Study	Recruiting	NCT03747783
15	Isolation, Quantification and Kinetics of Salivary Ap4A, SCCA and TROP2 in Patients With Oral Cancer and Potentially Malignant Oral Disorders	Active, not recruiting	NCT03529604

Search NIH Clinical Center for Laryngeal Squamous Cell Carcinoma

Sources

Genetic Tests for Laryngeal Squamous Cell Carcinoma

Sources

Anatomical Context for Laryngeal Squamous Cell Carcinoma

MalaCards organs/tissues related to Laryngeal Squamous Cell Carcinoma:

⁴⁰

Lymph Node, Thyroid, Endothelial, Neutrophil, T Cells, Breast, Skin

Sources

Publications for Laryngeal Squamous Cell Carcinoma

Articles related to Laryngeal Squamous Cell Carcinoma:

(show top 50) (show all 2019)

#	Title	Authors	PMID	Year
1	GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population. ⁵⁴ ⁶¹	Chatzimichalis M...Bibas A	19922706	2010
2	Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. ⁵⁴ ⁶¹	Zou J...Liu S	19741544	2010
3	EGFR immunoexpression and peripheral blood cytokine secretion as potential biomarkers of tumor behavior in laryngeal squamous cell carcinoma. ⁵⁴ ⁶¹	Starska K...Lukomski M	19789511	2009
4	Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract. ⁶¹ ⁵⁴	Farhadieh RD...Smee R	19669840	2009
5	Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. ⁶¹ ⁵⁴	Liao Z...Zhou Y	19375219	2009
6	[Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]. ⁵⁴ ⁶¹	Wang Z...Chen Y	19813623	2009
7	[The expressions and correlation of AQP1 and VEGF in laryngeal squamous cell carcinoma]. ⁵⁴ ⁶¹	Gao X...Liu J	19670620	2009
8	Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma. ⁶¹ ⁵⁴	Starska K...Lukomski M	19148533	2009
9	[The expression of Galectin-3 and VEGF in laryngeal squamous cell carcinoma]. ⁶¹ ⁵⁴	Kong H...Dong Z	19452726	2009
10	p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. ⁵⁴ ⁶¹	Jiang H...Yang BB	18607952	2009
11	Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck. ⁵⁴ ⁶¹	Farhadieh RD...Russell PJ	19183379	2009
12	Cell growth inhibition and down-regulation of survivin by silibinin in a laryngeal squamous cell carcinoma cell line. ⁶¹ ⁵⁴	Bang CI...Kim MS	18998509	2008
13	[hTERT promoter enhances the radiosensitivity to gene-radiation therapy of human laryngeal carcinoma transplanted in nude mice]. ⁶¹ ⁵⁴	Huang CH...Zhou YF	19173799	2008
14	[Study of the lymph node micrometastasis in patients with supraglottic carcinoma]. ⁶¹ ⁵⁴	Zhao J...Liu D	19166031	2008
15	Prognostic value of cell-cycle regulators and cellular biomarkers in laryngeal squamous cell carcinoma. ⁶¹ ⁵⁴	Swellam M...Adly A	18602381	2008
16	[Expression of angiopoietin-1,2 and its relationship with angiogenesis in laryngeal squamous cell carcinoma]. ⁵⁴ ⁶¹	Xu G...Zhang P	19086654	2008
17	[Effect of CDK2 on proliferation in laryngeal squamous cell carcinoma]. ⁵⁴ ⁶¹	Zhang H...Huangfu H	19166026	2008
18	Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma. ⁵⁴ ⁶¹	Micozkadioglu D...Cinel L	18509272	2008
19	[Detection of Skp2 mRNA gene expression using fluorogenic probe quantitative RT-PCR method in laryngeal squamous cell carcinoma]. ⁵⁴ ⁶¹	Guo J...Hu B	18800682	2008
20	Short hairpin ribonucleic acid targeting the telomerase catalytic unit of messenger ribonucleic acid significantly limits the growth of laryngeal squamous cell carcinoma in nude mice. ⁵⁴ ⁶¹	Zhou XH...Tao ZZ	17592663	2008
21	Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis. ⁶¹ ⁵⁴	Kitamura K...Suzuki M	18357366	2008
22	[Expression of cyclin G1 in laryngeal squamous cell carcinoma and its clinicopathologic significance]. ⁵⁴ ⁶¹	Cui XF...Chen XG	18788592	2008
23	[Expression of Survivin, Caspase-3 and p53 in surgical margin of laryngeal squamous cell carcinoma and their relationship]. ⁶¹ ⁵⁴	Du J...Su Y	18476631	2008
24	Possible prognostic role of p53 expression in laryngeal squamous cell carcinoma of non-smokers, non-alcoholic patients. ⁵⁴ ⁶¹	Fernandez-Acenero MJ...Ortega P	18607961	2008
25	Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. ⁵⁴ ⁶¹	Fu ZJ...Pan XL	18787961	2008
26	Expression of PTEN protein in patients with laryngeal squamous cell carcinoma. ⁵⁴ ⁶¹	Guney K...Cetin S	17475427	2007
27	[Effects of HPV 16-E6/E7 oncogene on expression of vascular endothelial growth factor and matrix metalloproteinase 9 in human laryngeal squamous cell carcinoma cell line]. ⁵⁴ ⁶¹	Cai P...Li JR	18307884	2007
28	Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. ⁶¹ ⁵⁴	Guan Z...Liu Q	17974987	2007
29	Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis. ⁵⁴ ⁶¹	Shigyo H...Harabuchi Y	17712678	2007
30	[Expression and clinical significance of Endostatin, vascular endothelial growth factor and fibroblast growth factor basic-2 in laryngeal carcinoma]. ⁶¹ ⁵⁴	Liu WW...Sun QF	18051571	2007
31	[Expression and role of survivin in laryngeal squamous cell carcinoma and laryngeal papilloma in adults]. ⁶¹ ⁵⁴	Xie H...Song F	17634026	2007
32	Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma (LSCC). ⁶¹ ⁵⁴	Xian J...Liu S	17328665	2007
33	[Clinical significance and expression of FLIP and PTEN protein in laryngeal squamous cell carcinoma]. ⁶¹ ⁵⁴	Wei Z...Zhou X	17441421	2007
34	The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma. ⁶¹ ⁵⁴	Gomatos IP...Ferekidou E	17264532	2007
35	[Expression and clinical significance of matrix metalloproteinase-2 in laryngeal squamous cell carcinoma]. ⁶¹ ⁵⁴	Wang X...Luo S	17357514	2006
36	[Expression of telomerase reverse transcriptase and its relationship with expression of c-myc in laryngeal squamous cell carcinomas]. ⁵⁴ ⁶¹	Chen Z...Jiang M	17219990	2006
37	5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. ⁵⁴ ⁶¹	Liu HC...van Hasselt CA	17207318	2006
38	Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis. ⁵⁴ ⁶¹	Marioni G...Staffieri A	17094406	2006
39	Relation of glutathione S-transferase genotypes (GSTM1 and GSTT1) to laryngeal squamous cell carcinoma risk. ⁵⁴ ⁶¹	Acar H...Ozer B	16938565	2006
40	Immunohistochemical estimation of cell cycle phase in laryngeal neoplasia. ⁶¹ ⁵⁴	Chatrath P...Coleman N	16832409	2006
41	[Construction of recombinant adenovirus vector carrying cell cycle controlling gene-p14ARF]. ⁶¹ ⁵⁴	Xian JM...Liu SX	16845966	2006
42	[The investigation of STK15 gene amplification and overexpression in laryngeal squamous cell carcinoma]. ⁶¹ ⁵⁴	Ye Y...Sun KL	16767676	2006
43	[The relationship between hypermethylation of the PTEN promoter and laryngeal squamous cell carcinoma]. ⁵⁴ ⁶¹	Bai W...Wang T	16739377	2006
44	[The clinical significance of the expression of p63 gene in laryngeal squamous cell carcinoma]. ⁶¹ ⁵⁴	Jia H...Hou J	16646404	2006
45	[Inhibitory effect of silencing hTERT gene by short hairpin RNA on growth of human laryngeal squamous cell carcinoma xenograft in nude mice]. ⁵⁴ ⁶¹	Liu D...Chi HM	16405742	2006
46	TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. ⁶¹ ⁵⁴	Russo A...Bazan V	15965904	2006
47	[The correlation of vascular endothelial growth factor with angiogenesis and p53 gene in laryngeal squamous cell carcinoma]. ⁵⁴ ⁶¹	Yaylaci A...Gokceer T	16763427	2006
48	Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance. ⁵⁴ ⁶¹	Chen G...Gong S	16711020	2006
49	Promoter hypermethylation of DNA repair gene MGMT in laryngeal squamous cell carcinoma. ⁶¹ ⁵⁴	Zhang S...Liu Z	16711019	2006
50	Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. ⁵⁴ ⁶¹	Gorogh T...Maune S	16265652	2006

Sources

Genes for Laryngeal Squamous Cell Carcinoma

Genes related to Laryngeal Squamous Cell Carcinoma (0 elite genes):

(show all 40)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MIR21	MicroRNA 21	RNA Gene	166.75	Experimental evidence ³⁸ DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)	25099764
2	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	163.23	Experimental evidence: Regulation ³⁸ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	23141928 24817925 25099764 (more) 25257554 27542077
3	LINC01537	Long Intergenic Non-Protein Coding RNA 1537	RNA Gene	161.84	Experimental evidence: Regulation ³⁸ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	25243407
4	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	161.06	Experimental evidence: Regulation ³⁸ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	28631575
5	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	159.71	Experimental evidence: Regulation ³⁸ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	24817925 25257554
6	MTCO1P5	MT-CO1 Pseudogene 5	Pseudogene	156.47	Experimental evidence: Regulation ³⁸ GeneCards inferred via : Publications (show sections)	25243407
7	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	156.12	Experimental evidence: Regulation ³⁸ GeneCards inferred via : Publications (show sections)	26872375
8	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	RNA Gene	155.72	Experimental evidence: Regulation ³⁸ DISEASES inferred ¹⁵	26822763
9	HOXA11-AS	HOXA11 Antisense RNA	RNA Gene	155.03	Experimental evidence: Expression ³⁸ DISEASES inferred ¹⁵	29511452
10	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	154.94	Experimental evidence: Regulation ³⁸ DISEASES inferred ¹⁵	25257554
11	RRP1B	Ribosomal RNA Processing 1B	Protein Coding	150	Experimental evidence: Regulation ³⁸	25257554
12	SRA1	Steroid Receptor RNA Activator 1	Protein Coding	150	Experimental evidence: Regulation ³⁸	25257554
13	TP53	Tumor Protein P53	Protein Coding	23.46	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	9294474 18607961 12526287 (more) 15023836 9515767 8803594 10368653 11131662 18788592 14995078 9868114 18476631 15965904 11829192 12545812 19582341 17207318 16398049 15279637 15199601 7850072 16340285 12642632 11320623 9267820 12514403 18607952 12883724 11520092 10875157 9281367 10323025 7829392 16739381 15663083 11012985 10562812 9563667 7599785 18357366 16763427 11956639 11836691 12600081 10942137 10448265 9950162 19183379 11400228 8762527 7882279 12561442 11016683 8639294 14681317 7788934 18509272 12761985 12761983 9610695 10419041 10191626 14690561
14	CCND1	Cyclin D1	Protein Coding	21.82	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	12563983 17139501 9829720 (more) 11400112 16832409 12669430 16327270 19681484 9816104 16116829
15	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	21.78	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	15071918 10323033 12778765 (more) 12768709 18787961 12812651 16845966 15473298 12761983 10194257 18602381 12761910 18357366 11836682 16760277
16	EGFR	Epidermal Growth Factor Receptor	Protein Coding	21.23	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	9644164 11751491 9271009 (more) 18607952 19669840 15473298 17328665 19789511 8883413 1442018 1991297 12669431 19148533 8667988 10435153 12541423 11668514 14649542 10096253 7793243 15848906 10191626
17	AURKA	Aurora Kinase A	Protein Coding	20.27	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	12812651 16767676 17974987 (more) 12693093 16377583 15192826
18	NME1	NME/NM23 Nucleoside Diphosphate Kinase 1	Protein Coding	19.68	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	8635091 9642340 12014221 (more) 11189167 9555115
19	CDH1	Cadherin 1	Protein Coding	19.48	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	19741544 9816133 10609562 (more) 16941960 16259108 15848906 16404343 11956639
20	TERT	Telomerase Reverse Transcriptase	Protein Coding	19.42	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	17592663 17219990 15823813 (more) 11911285 16405742 19173799 19375219 16739381
21	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	19.23	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	15510660 10782883 16124648 (more) 16711020 15362688 19670620 19452726 16408728 19086654 11843932 18307884 16763427 17712678 15831042 18051571 9426404
22	PTEN	Phosphatase And Tensin Homolog	Protein Coding	19	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16739377 17441421 15831044 (more) 16075977 17357516 15127561 17475427 14720383
23	SKP2	S-Phase Kinase Associated Protein 2	Protein Coding	18.64	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	12579266 16075976 19961778 (more) 18800682
24	MMP2	Matrix Metallopeptidase 2	Protein Coding	18.05	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	15746850 17357514 17341208 (more) 14729463 9555115 16265652
25	BIRC5	Baculoviral IAP Repeat Containing 5	Protein Coding	17.97	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	18998509 12174930 15279637 (more) 16375115 16176004 18476631 15566665 16013505 17634026 15191673 16075977 17094406
26	GSTM3	Glutathione S-Transferase Mu 3	Protein Coding	17.97	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	19922706
27	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	Protein Coding	17.78	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	15473298 12812651 18602381 (more) 11836682
28	MCM2	Minichromosome Maintenance Complex Component 2	Protein Coding	17.25	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16832409 12966424
29	CCNB1	Cyclin B1	Protein Coding	17.16	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	11809526 16832409
30	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	16.99	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	11189153
31	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	16.87	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	15522186 16013507 15906520 (more) 18357366
32	MIR744	MicroRNA 744	RNA Gene	16.63	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
33	CDK2	Cyclin Dependent Kinase 2	Protein Coding	16.32	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	19166026 11299721
34	MIR34A	MicroRNA 34a	RNA Gene	16.12	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
35	MIR155	MicroRNA 155	RNA Gene	16	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
36	KRT19	Keratin 19	Protein Coding	15.86	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	19166031
37	MIR148A	MicroRNA 148a	RNA Gene	15.84	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
38	GSTM1	Glutathione S-Transferase Mu 1	Protein Coding	15.8	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16938565 15914211 19922706
39	PCNA	Proliferating Cell Nuclear Antigen	Protein Coding	15.76	Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	15844604 12740649 16995968 (more) 18607952 9097710 15199601 10824607 8762515 12378803 11410133 8745457 16512489 10435153 10684010 11400112 15791865 18509272 9816133 9624390
40	EIF4E	Eukaryotic Translation Initiation Factor 4E	Protein Coding	15.53	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	12838026 16124648 15510630 (more) 12889116

Sources

Variations for Laryngeal Squamous Cell Carcinoma

Cosmic variations for Laryngeal Squamous Cell Carcinoma:

⁹

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM122736330		upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.338G>T	p.G113V	17:7674229-7674229	0

Sources

Expression for Laryngeal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Laryngeal Squamous Cell Carcinoma.

Sources

Pathways for Laryngeal Squamous Cell Carcinoma

Pathways related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²² Thyroid cancer ³⁶	12.72	TP53 EGFR CDKN2A CDH1 CCND1
2	Pathways in cancer ³⁶	12.57	TP53 TERT EGFR CDKN2A CDH1 CCND1
3	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	12.47	TP53 EGFR CDKN2A CDH1 CCND1
4	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.4	TP53 TERT EGFR CDKN2A CDH1 CCND1
5	MicroRNAs in cancer ³⁶	12.32	TP53 MIR21 EGFR CDKN2A CCND1
6	Cell cycle ³⁶ ¹	12.2	TP53 CDKN2A CDH1 CCND1
7	Human T-cell leukemia virus 1 infection ³⁶	12.17	TP53 TERT CDKN2A CCND1
8	Proteoglycans in cancer ³⁶	12.11	TP53 MIR21 EGFR CCND1
9	Colorectal Cancer Metastasis ⁶³	11.98	TP53 EGFR CDH1 CCND1
10	Integrated Breast Cancer Pathway ¹	11.74	TP53 EGFR CDH1 CCND1 AURKA
11	Glioblastoma Multiforme ⁶³	11.67	TP53 EGFR CDKN2A CCND1
12	Validated targets of C-MYC transcriptional activation ¹	11.64	TP53 TERT NME1
13	Regulation of Wnt-mediated beta catenin signaling and target gene transcription ¹	11.62	TERT CDH1 CCND1
14	Regulation of Telomerase ¹	11.51	TERT EGFR CCND1
15	E-cadherin signaling in the nascent adherens junction ¹	11.1	NME1 CDH1 CCND1
16	Photodynamic therapy-induced AP-1 survival signaling. ¹	10.96	TP53 EGFR CDKN2A CCND1
17	Bladder cancer ³⁶ ¹	10.88	TP53 EGFR CDKN2A CDH1 CCND1
18	LncRNA-mediated mechanisms of therapeutic resistance ¹	10.65	TP53 HOTAIR

Sources

GO Terms for Laryngeal Squamous Cell Carcinoma

Biological processes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	9.89	TP53 TERT MIR21 EGFR AURKA
2	positive regulation of inflammatory response	GO:0050729	9.69	NEAT1 MIR21 EGFR
3	regulation of protein stability	GO:0031647	9.65	TERT CDKN2A AURKA
4	cellular response to drug	GO:0035690	9.61	TP53 NME1 EGFR
5	positive regulation of epithelial cell proliferation	GO:0050679	9.54	NME1 EGFR CCND1
6	positive regulation of G1/S transition of mitotic cell cycle	GO:1900087	9.5	TERT EGFR CCND1
7	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.46	TP53 EGFR
8	mitotic G1 DNA damage checkpoint	GO:0031571	9.4	TP53 CCND1
9	liver regeneration	GO:0097421	9.33	EGFR CCND1 AURKA
10	response to UV-A	GO:0070141	9.26	EGFR CCND1
11	negative regulation of gene expression	GO:0010629	9.17	TP53 TERT NME1 MIR21 HOXA11-AS CDKN2B-AS1
12	replicative senescence	GO:0090399	9.13	TP53 TERT CDKN2A

Molecular functions related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase binding	GO:0019901	9.02	TP53 EGFR CDKN2A CCND1 AURKA

Sources

Sources for Laryngeal Squamous Cell Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia